Head-To-Head Comparison: PTC Therapeutics (NASDAQ:PTCT) versus CollPlant Biotechnologies (NASDAQ:CLGN)

PTC Therapeutics (NASDAQ:PTCT – Get Free Report) and CollPlant Biotechnologies (NASDAQ:CLGN – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, earnings, risk, institutional ownership and profitability.

Risk and Volatility

PTC Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the S&P 500. Comparatively, CollPlant Biotechnologies has a beta of 1.66, suggesting that its share price is 66% more volatile than the S&P 500.

Insider and Institutional Ownership

21.7% of CollPlant Biotechnologies shares are owned by institutional investors. 5.3% of PTC Therapeutics shares are owned by company insiders. Comparatively, 9.6% of CollPlant Biotechnologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for PTC Therapeutics and CollPlant Biotechnologies, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PTC Therapeutics 1 3 10 1 2.73
CollPlant Biotechnologies 1 1 0 0 1.50

PTC Therapeutics currently has a consensus target price of $99.23, indicating a potential upside of 62.75%. CollPlant Biotechnologies has a consensus target price of $120.00, indicating a potential upside of 2,431.65%. Given CollPlant Biotechnologies’ higher possible upside, analysts clearly believe CollPlant Biotechnologies is more favorable than PTC Therapeutics.

Profitability

This table compares PTC Therapeutics and CollPlant Biotechnologies’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
PTC Therapeutics -9.17% N/A -0.10%
CollPlant Biotechnologies -678.37% -298.21% -167.83%

Valuation and Earnings

This table compares PTC Therapeutics and CollPlant Biotechnologies”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
PTC Therapeutics $1.16 billion 4.41 $682.64 million ($1.40) -43.55
CollPlant Biotechnologies $2.37 million 3.78 -$11.49 million ($13.59) -0.35

PTC Therapeutics has higher revenue and earnings than CollPlant Biotechnologies. PTC Therapeutics is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Summary

PTC Therapeutics beats CollPlant Biotechnologies on 10 of the 15 factors compared between the two stocks.

About PTC Therapeutics

(Get Free Report)

PTC Therapeutics is a biopharmaceutical company focused on discovering, developing and commercializing medicines for rare diseases. Founded in 1998 and headquartered in Warren, New Jersey, the company works across several therapeutic areas, including genetic and neurological disorders. Its products include Kebilidi (eladocagene exuparvovec), a gene therapy for aromatic L-amino acid decarboxylase deficiency, and Sephience (sepiapterin), a treatment for phenylketonuria. PTC has also developed medicines for Duchenne muscular dystrophy, including ataluren, marketed as Translarna in some regions.

About CollPlant Biotechnologies

(Get Free Report)

CollPlant Biotechnologies is an Israel-based regenerative medicine company developing products and technologies based on recombinant human collagen (rhCollagen). Its proprietary production process uses genetically engineered plants to produce human collagen, offering an alternative to collagen sourced from animals or human tissue. The company’s rhCollagen platform is intended for applications including tissue repair, 3D bioprinting and medical aesthetics. Its development work includes bioinks and other collagen-based materials designed for use in regenerative medicine and tissue engineering.

Receive News & Ratings for PTC Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PTC Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.